Results 101 to 110 of about 96,425 (243)
ABSTRACT Succinylation has been shown to promote lung cancer development, but its mechanism remains incompletely understood. KAT2A, a succinyltransferase, acts as an oncogene in multiple cancers, but its role in mediating lung cancer progression is unclear.
Junping Li +7 more
wiley +1 more source
Upon chemotherapy, a subset of cancer cells enters a senescent state, referred to as TIS. When IAP antagonists are administered, TIS cells are selectively eliminated through TNFα‐independent apoptosis. TNFα secreted by TIS cancer cells may also act in a paracrine manner to enhance extrinsic apoptosis in neighboring non‐senescent cancer cells.
Hiroaki Ochiiwa +7 more
wiley +1 more source
The subcellular distribution of cyclin-D1 and cyclin-D3 within human islet cells varies according to the status of the pancreas donor [PDF]
Kazuto Taniguchi +3 more
openalex +1 more source
The micropeptide altH19 interacts with phosphorylated CDK2 (p‐CDK2), subsequently activating CDK2 phosphorylation. This enhances the downstream E2F1 target gene RB activity, which accelerates DNA replication, ultimately leading to rapid myeloma cell mitosis and proliferation.
Yaxin Zhang +6 more
wiley +1 more source
Kdf1 Regulates Molar Cusp Morphogenesis via the PI3K/AKT/mTOR Signalling Axis
Epithelial Kdf1 knockout disrupts molar cusp morphogenesis by promoting inner enamel epithelium proliferation and invagination via PI3K/AKT/mTOR signalling. ABSTRACT Keratinocyte differentiation factor 1 (Kdf1) reportedly plays a significant role in enamel formation.
Jiayu Wang +9 more
wiley +1 more source
Correction: Identification of a naturally processed cyclin D1 T‐helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry (Vol. 34(12) 2004, p. 3644–3651) [PDF]
J�rn Dengjel +6 more
openalex +1 more source
Non‐coding RNAs (ncRNAs) regulate breast cancer radioresistance via cell cycle, DNA repair and tumour microenvironment pathways. Targeting ncRNAs (e.g., HOTAIR and miR‐155) with RNA‐based therapies (ASOs and CRISPR) shows promise but faces delivery challenges.
Xiaohui Zhao +8 more
wiley +1 more source

